STOCK TITAN
  1. Home
  2. Sec-filings
  3. EW
  4. [Form 4] Edwards Lifesciences Corp Insider Trading Activity

Edwards Lifesciences (EW) director granted new stock awards and updates holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LORANGER STEVEN R reported acquisition or exercise transactions in this Form 4 filing.

Edwards Lifesciences director Steven R. Loranger reported equity awards and updated holdings. On May 8, 2026, he received 1,064 restricted stock units and a 3,251-share restricted stock award at $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program. Both awards are scheduled to vest 100% after the earlier of one year from the grant date or the company’s next annual stockholders’ meeting. Following these grants, he directly holds 8,997 shares and indirectly holds 75,372 shares through a trust.

Positive

  • None.

Negative

  • None.
Insider LORANGER STEVEN R
Role null
Type Security Shares Price Value
Grant/Award Common Stock 3,251 $0.00 --
Grant/Award Common Stock 1,064 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 7,933 shares (Direct, null); Common Stock — 75,372 shares (Indirect, By Trust)
Footnotes (1)
  1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Restricted stock units granted 1,064 shares Granted May 8, 2026 under 2020 Nonemployee Directors Stock Incentive Program
Restricted stock award 3,251 shares Granted May 8, 2026 under 2020 Nonemployee Directors Stock Incentive Program
Grant price $0.00 per share Equity compensation awards, not open-market purchases
Direct holdings after grants 8,997 shares Common stock directly owned after May 8, 2026 transactions
Indirect holdings by trust 75,372 shares Common stock held indirectly through a trust as of May 8, 2026
restricted stock units financial
"These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
restricted stock award financial
"This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program."
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
2020 Nonemployee Directors Stock Incentive Program financial
"under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LORANGER STEVEN R
(Last)(First)(Middle)
ONE EDWARDS WAY
(Street)
IRVINE CALIFORNIA 92614
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/08/2026A3,251(1)A$0.00007,933D
Common Stock05/08/2026A1,064(2)A$0.00008,997D
Common Stock75,372IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
2. This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Edwards Lifesciences (EW) director Steven R. Loranger report in this Form 4?

Steven R. Loranger reported equity compensation awards in Edwards Lifesciences common stock. He received restricted stock units and a restricted stock award, and the filing updates his direct and indirect share holdings as of the May 8, 2026 grant date.

How many Edwards Lifesciences (EW) shares did Steven R. Loranger receive?

He received 1,064 restricted stock units and a 3,251-share restricted stock award. Both awards were granted at $0.00 per share as compensation rather than open-market purchases, reflecting standard nonemployee director equity incentives.

When do Steven R. Loranger’s new Edwards Lifesciences (EW) awards vest?

Both the 1,064 restricted stock units and the 3,251-share restricted stock award are scheduled to become 100% vested after the earlier of one year from the May 8, 2026 grant date or Edwards Lifesciences’ next annual meeting of stockholders.

How many Edwards Lifesciences (EW) shares does Steven R. Loranger hold after these transactions?

After the May 8, 2026 awards, he directly holds 8,997 shares of Edwards Lifesciences common stock. He also has an indirect holding of 75,372 shares through a trust, as reported in the Form 4 filing.

Are Steven R. Loranger’s Edwards Lifesciences (EW) Form 4 transactions open-market buys or sales?

No, the Form 4 shows compensation-related acquisitions coded as “A,” not open-market trades. The grants were issued at $0.00 per share under the 2020 Nonemployee Directors Stock Incentive Program and reflect routine nonemployee director equity awards.

Under what plan were Steven R. Loranger’s Edwards Lifesciences (EW) equity awards granted?

Both the restricted stock units and the restricted stock award were granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program, which provides stock-based compensation to nonemployee members of the company’s board of directors.